Patrick N. Harter
YOU?
Author Swipe
View article: IMG-106. Defining measurable disease as inclusion criterion in glioblastoma trials - a retrospective, comparative study of PET RANO 1.0 vs. RANO 2.0 criteria after radiotherapy and at first progression
IMG-106. Defining measurable disease as inclusion criterion in glioblastoma trials - a retrospective, comparative study of PET RANO 1.0 vs. RANO 2.0 criteria after radiotherapy and at first progression Open
Glioblastoma response assessment relies on MRI-based RANO 2.0 criteria, where the presence of measurable disease often is required for clinical trial eligibility. Key enrollment timepoints include the post-radiotherapy period and first rec…
View article: IMG-86. Spatial patterns of [68Ga]Ga-PSMA-11 or [18F]PSMA-1007 PET uptake in comparison with [18F]FET PET and contrast-enhanced MRI in brain tumors
IMG-86. Spatial patterns of [68Ga]Ga-PSMA-11 or [18F]PSMA-1007 PET uptake in comparison with [18F]FET PET and contrast-enhanced MRI in brain tumors Open
INTRODUCTION Radioligand therapies represent an area of increasing interest in brain tumors. Prostate-specific membrane antigen (PSMA)-targeted treatment by [177Lu]Lu-PSMA-617 is approved in prostate cancer, and immunohistochemical studies…
View article: IMG-83. [18F]Fluoroethyltyrosine and [11C]methionine PET for prognostic stratification of newly diagnosed <i>IDH</i> -mutant gliomas – a retrospective, bicentric cohort study
IMG-83. [18F]Fluoroethyltyrosine and [11C]methionine PET for prognostic stratification of newly diagnosed <i>IDH</i> -mutant gliomas – a retrospective, bicentric cohort study Open
INTRODUCTION Given the changing treatment landscape in IDH-mutant gliomas, prognostic stratification is pivotal to guide postoperative treatment decisions. METHODS Overall, 457 patients with IDH-mutant glioma and [18F]fluoroethyltyrosine o…
View article: IMG-103. Molecular Characterization of Meningiomas with Low SSTR-PET/CT Uptake: Insights from a Case Series
IMG-103. Molecular Characterization of Meningiomas with Low SSTR-PET/CT Uptake: Insights from a Case Series Open
Meningiomas are generally characterized by high expression of somatostatin receptors (SSTRs), which makes them suitable candidates for PET imaging with SSTR-directed tracers such as 68Ga-DOTATATE. However, certain meningiomas demonstrate l…
View article: IMG-50. Identifying residual tumor burden following glioblastoma resection: A comparative analysis of MR-based RANOresect classes vs.[18F]FET-PET
IMG-50. Identifying residual tumor burden following glioblastoma resection: A comparative analysis of MR-based RANOresect classes vs.[18F]FET-PET Open
BACKGROUND Extensive resection improves glioblastoma survival, with residual tumor volume as a key prognostic marker. The RANO resect group proposed a classification based on postoperative MRI volume. With [18F]FET-PET is increasingly used…
View article: IMG-84. Somatostatin receptor (SSTR) PET positivity definitions as eligibility criterion for SSTR-targeted radioligand therapies: a retrospective comparative study
IMG-84. Somatostatin receptor (SSTR) PET positivity definitions as eligibility criterion for SSTR-targeted radioligand therapies: a retrospective comparative study Open
BACKGROUND Retrospective and small prospective studies of [177Lu]Lu-DOTATATE treatment suggest clinical activity in meningioma. Frequently, pretherapeutic SSTR expression as determined by SSTR PET is used to evaluate eligibility for such t…
View article: IMG-44. Measurable disease for response assessment in IDH-mutant glioma – a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment
IMG-44. Measurable disease for response assessment in IDH-mutant glioma – a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment Open
PURPOSE In clinical trials for patients with IDH-mutant gliomas, “measurable disease” on MRI is a key inclusion criterion for MRI-based response assessment. Recently, amino acid PET-based criteria have been proposed for response assessment…
View article: IMG-79. Application of the PET RANO BM 1.0 criteria in brain metastases: a retrospective single center experience
IMG-79. Application of the PET RANO BM 1.0 criteria in brain metastases: a retrospective single center experience Open
BACKGROUND The new PET RANO BM 1.0 criteria offer a standardized framework for response assessment in brain metastases using amino acid PET, whereas clinical practice and trials have primarily relied on MRI. This study applies the new crit…
View article: IMG-81. Application of the PET RANO 1.0 criteria in diffuse glioma: a retrospective, single-center, real-world experience
IMG-81. Application of the PET RANO 1.0 criteria in diffuse glioma: a retrospective, single-center, real-world experience Open
RATIONALE Response evaluation and disease monitoring of gliomas rely on MRI in clinical routine and trials. Recently, novel response criteria utilizing amino acid PET (PET RANO 1.0) have been introduced. This study analyzes longitudinal [1…
View article: Time matters: the prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma—a single-center, retrospective real-world study
Time matters: the prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma—a single-center, retrospective real-world study Open
Background Primary central nervous system lymphoma (PCNSL) is a rare and aggressive malignancy that frequently mimics other central nervous system (CNS) diseases, leading to diagnostic delays. Given its often nonspecific radiological prese…
View article: Glioma‑associated microglia and macrophages as a potential target for mTOR inhibition in glioblastoma
Glioma‑associated microglia and macrophages as a potential target for mTOR inhibition in glioblastoma Open
Glioma‑associated microglia/macrophages (GAM) constitute the predominant immune cell population in glioblastoma (GB). Both GB cells and GAM exhibit upregulated mTOR signaling. The present study aimed to investigate the effects of pharmacol…
View article: P11.30.A IMMUNOMODULATORY EFFECTS OF PREOPERATIVE STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES: PROSPECTIVE INTEGRATION OF TISSUE AND CEREBROSPINAL FLUID PROFILING
P11.30.A IMMUNOMODULATORY EFFECTS OF PREOPERATIVE STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES: PROSPECTIVE INTEGRATION OF TISSUE AND CEREBROSPINAL FLUID PROFILING Open
BACKGROUND Brain metastases (BM) are among the most common malignant brain tumors in adults, associated with poor prognosis and limited therapeutic options. Preoperative stereotactic radiosurgery (SRS) is emerging as a novel local treatmen…
View article: P18.25.B SPATIALLY CONFINED TRANSCRIPTIONAL RESPONSES CHARACTERIZE THE EARLY PRE-METASTATIC NICHE IN BRAIN METASTASIS
P18.25.B SPATIALLY CONFINED TRANSCRIPTIONAL RESPONSES CHARACTERIZE THE EARLY PRE-METASTATIC NICHE IN BRAIN METASTASIS Open
BACKGROUND Brain metastases often originate from circulating tumor cells (CTCs) that become arrested within cerebral microvessels. Recent findings indicate that this process induces localized hypoxia, which in turn upregulates angiogenic m…
View article: P03.21.B IDENTIFYING RESIDUAL TUMOR BURDEN FOLLOWING GLIOBLASTOMA RESECTION: A COMPARATIVE ANALYSIS OF MR-BASED RANO RESECT CLASSES VS.[18F]FET-PET
P03.21.B IDENTIFYING RESIDUAL TUMOR BURDEN FOLLOWING GLIOBLASTOMA RESECTION: A COMPARATIVE ANALYSIS OF MR-BASED RANO RESECT CLASSES VS.[18F]FET-PET Open
BACKGROUND Extensive resection improves glioblastoma survival, with residual tumor volume as a key prognostic marker. The RANO resect group proposed a classification based on postoperative MRI volume. With [18F]FET-PET increasingly used fo…
View article: JS03.6.A COMPARISON OF [18F]SITATE PET POSITIVITY DEFINITIONS AS ELIGIBILITY CRITERION FOR SOMATOSTATIN RECEPTOR-TARGETED RADIOLIGAND THERAPIES
JS03.6.A COMPARISON OF [18F]SITATE PET POSITIVITY DEFINITIONS AS ELIGIBILITY CRITERION FOR SOMATOSTATIN RECEPTOR-TARGETED RADIOLIGAND THERAPIES Open
BACKGROUND Clinical trials evaluating [177Lu]Lu-DOTATATE treatment in meningioma are ongoing. While somatostatin receptor (SSTR) expression is used as inclusion criterion, definitions of SSTR-positivity (SSTR+) in PET are manifold and poor…
View article: P03.23.B PROGNOSTIC STRATIFICATION OF NEWLY DIAGNOSED IDH-MUTANT GLIOMAS BASED ON QUANTITATIVE AMINO ACID PET PARAMETERS AND MRI-BASED TUMOR EXTENT
P03.23.B PROGNOSTIC STRATIFICATION OF NEWLY DIAGNOSED IDH-MUTANT GLIOMAS BASED ON QUANTITATIVE AMINO ACID PET PARAMETERS AND MRI-BASED TUMOR EXTENT Open
BACKGROUND Given the changing treatment landscape in IDH-mutant glioma, there is an urgent need for refined prognostic stratification in the newly diagnosed setting. While amino acid PET is increasingly used in the clinical management, the…
View article: P03.25.B CLINICAL UTILITY OF [18F]FET PET IN PATIENTS WITH CIRCUMSCRIBED ASTROCYTIC GLIOMA
P03.25.B CLINICAL UTILITY OF [18F]FET PET IN PATIENTS WITH CIRCUMSCRIBED ASTROCYTIC GLIOMA Open
BACKGROUND O-(2-[18F]fluoroethyl)-L-tyrosine ([¹⁸F]FET) PET is predominantly applied for molecular imaging of diffuse gliomas. In contrast, data on the clinical utility of [¹⁸F]FET PET in circumscribed astrocytic gliomas (CAG) remain scarc…
View article: P17.36.B TIME MATTERS: THE PROGNOSTIC IMPACT OF DIAGNOSTIC DELAY ON SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - A SINGLE-CENTER, RETROSPECTIVE REAL-WORLD STUDY
P17.36.B TIME MATTERS: THE PROGNOSTIC IMPACT OF DIAGNOSTIC DELAY ON SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - A SINGLE-CENTER, RETROSPECTIVE REAL-WORLD STUDY Open
BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare and aggressive malignancy that frequently mimics other central nervous system (CNS) diseases, leading to diagnostic delays. Given its often nonspecific radiological prese…
View article: P05.14.B MULTI-LAYERED CEREBROSPINAL FLUID LIQUID BIOPSY OF INFLAMMATORY AND ONCOLOGICAL CNS DISEASES
P05.14.B MULTI-LAYERED CEREBROSPINAL FLUID LIQUID BIOPSY OF INFLAMMATORY AND ONCOLOGICAL CNS DISEASES Open
BACKGROUND For diagnosis of central nervous system (CNS) pathologies, invasive procedures such as tissue biopsies are often indicated. The use of cerebrospinal fluid (CSF) for a liquid biopsy (LB) has promise as a minimal invasive tool, no…
View article: P03.20.A DEFINING MEASURABLE DISEASE AS INCLUSION CRITERION IN GLIOBLASTOMA TRIALS - A RETROSPECTIVE, COMPARATIVE STUDY OF PET RANO 1.0 VS. RANO 2.0 CRITERIA AFTER RADIOTHERAPY AND FIRST PROGRESSION
P03.20.A DEFINING MEASURABLE DISEASE AS INCLUSION CRITERION IN GLIOBLASTOMA TRIALS - A RETROSPECTIVE, COMPARATIVE STUDY OF PET RANO 1.0 VS. RANO 2.0 CRITERIA AFTER RADIOTHERAPY AND FIRST PROGRESSION Open
PURPOSE Response assessment in glioblastoma is based on the evaluation of contrast enhancement on MRI using RANO 2.0 criteria. ‘Measurable disease’ serves as an inclusion criterion for clinical trials both at baseline after radiotherapy an…
View article: OS06.5.A MODULATING TUMOR-ASSOCIATED MACROPHAGES TO ENHANCE EPCAM-DIRECTED CAR T CELL EFFICACY IN LUNG CANCER BRAIN METASTASES
OS06.5.A MODULATING TUMOR-ASSOCIATED MACROPHAGES TO ENHANCE EPCAM-DIRECTED CAR T CELL EFFICACY IN LUNG CANCER BRAIN METASTASES Open
BACKGROUND Immunotherapies in the treatment of brain metastases remain a major challenge largely due to the highly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages and microglia (TAM/M) have emerged as key media…
View article: A Novel Vascular Model Yields Increased MR Perfusion Metrics Compared to Conventional Dynamic Susceptibility Contrast Algorithms In Untreated Glioblastoma
A Novel Vascular Model Yields Increased MR Perfusion Metrics Compared to Conventional Dynamic Susceptibility Contrast Algorithms In Untreated Glioblastoma Open
Background Malignant gliomas are heterogeneous brain tumors with extensive neovascularization. Conventional gradient-echo dynamic susceptibility contrast (GRE-DSC) perfusion MRI may underestimate microvascular alterations. We hypothesized …
View article: DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma
DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma Open
View article: Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3
Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3 Open
Background The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas b…
View article: crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors Open
DNA methylation-based classification of (brain) tumors has emerged as a powerful and indispensable diagnostic technique. Initial implementations used methylation microarrays for data generation, while most current classifiers rely on a fix…
View article: BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma
BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma Open
Resistance to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) plus mitogen-activated protein kinase kinase (MEK) inhibition (BRAFi+MEKi) in BRAFV600E-mutant gliomas drives rebound, progression, and high mortality, yet it r…
View article: Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification Open
DNA methylation-based classification is integral to contemporary neuro-oncological diagnostics, as highlighted by the current World Health Organization (WHO) classification of central nervous system (CNS) tumors. We introduce the Heidelber…
View article: AMP-activated protein kinase mediates adaptation of glioblastoma cells to conditions of the tumor microenvironment
AMP-activated protein kinase mediates adaptation of glioblastoma cells to conditions of the tumor microenvironment Open
AMP-activated protein kinase (AMPK) is an energy sensor that regulates cellular metabolic activity. We hypothesized that in glioblastoma (GB), AMPK plays a pivotal role in balancing metabolism under conditions of the tumor microenvironment…
View article: Decoding the immune response in leptomeningeal disease through single-cell sequencing of cerebrospinal fluid
Decoding the immune response in leptomeningeal disease through single-cell sequencing of cerebrospinal fluid Open
Assessing anti-tumor immune responses and immune microenvironments in central nervous system (CNS) neoplasms, such as brain tumors and leptomeningeal disease (LMD), provides prognostic insights and predictive biomarkers. Liquid biopsy of t…
View article: AI-based Personalized Survival Predictions For Ependymoma Patients Using DNA Methylation Profiling
AI-based Personalized Survival Predictions For Ependymoma Patients Using DNA Methylation Profiling Open